麻豆传媒

Flecks of leftover intertwined with the genetics of modern humans may help cancer survive. (U.S. News & World Report)

The Centers for Medicare and Medicaid Services' interpretation of the Inflation Reduction Act's authority may delay access to promising therapies, the president of Severn Health Solutions argued. (STAT)

A New Jersey judge refused to disqualify key opponents of Johnson & Johnson's stemming from the company's talc products. (Reuters)

The (ASCO) appealed to oncologists to share their personal stories about drug shortages and the importance of federal support for cancer research as Congress prepares to act on legislation that could affect patients and providers for years to come.

MAIA Biotechnology announced positive results from the first patients with non-small cell lung cancer treated with its THIO followed by the PD-1 inhibitor cemiplimab (Libtayo).

The FDA issued for how manufacturers should report post-approval manufacturing changes for biosimilars and interchangeable products.

The agency also issued for use of real-world data in regulatory submissions.

Jaguar Health announced that a phase III trial of crofelemer (Mytesi) for diarrhea prophylaxis across multiple types of solid tumors.

Two reduced-dose strategies for radiopharmaceutical products to treat worked as well as standard dosing but with less toxicity. (Society of Nuclear Medicine and Molecular Imaging)

Does exposure to pose a greater cancer risk than smoking? (Frontiers in Cancer Control and Society)

Principal toxicities associated with CAR T-cell therapy rarely occur after the first 2 weeks, creating a potential to reduce the by half. (Blood Advances)

Comment